scispace - formally typeset
E

Edwin D. Charlebois

Researcher at University of California, San Francisco

Publications -  236
Citations -  13880

Edwin D. Charlebois is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Population & Acquired immunodeficiency syndrome (AIDS). The author has an hindex of 60, co-authored 216 publications receiving 12742 citations. Previous affiliations of Edwin D. Charlebois include University of California, Berkeley & University of Pennsylvania.

Papers
More filters
Journal ArticleDOI

Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population.

TL;DR: A substantial proportion of homeless and marginally housed individuals had good adherence to PI therapy and a strong relationship was found between independent methods of measuring adherence and concurrent viral suppression.
Journal ArticleDOI

Non-adherence to highly active antiretroviral therapy predicts progression to Aids

TL;DR: The introduction of highly active antiretroviral therapy (HAART) has produced a dramatic reduction in mortality among HIV-infected individuals, and the level of adherence to HAART is closely associated with suppression of the HIV viral load in plasma.
Journal ArticleDOI

High prevalence of methicillin-resistant Staphylococcus aureus in emergency department skin and soft tissue infections

TL;DR: In this urban ED population, MRSA is a major pathogen in skin and soft tissue infections and should be considered when empiric antibiotic therapy is selected for such infections.
Journal ArticleDOI

Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale.

TL;DR: A visual analogue scale to assess adherence was performed as well as a more complicated 3-day recall instrument in this diverse population of HIV-infected patients, and may be useful in routine patient care.
Journal ArticleDOI

Decline in HIV infectivity following the introduction of highly active antiretroviral therapy.

TL;DR: Use of HAART by infected persons in a community appears to reduce their infectiousness and therefore may provide an important HIV prevention tool.